Related Experiment Video

Updated: May 24, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in

Daniela Molè1, Erica Gentilin, Teresa Gagliano

  • 1Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Via Savonarola 9, 44121 Ferrara, Italy.

Endocrinology
|March 1, 2012
PubMed

Insights

Protein kinase C (PKC) inhibition with Enzastaurin reduces medullary thyroid carcinoma (MTC) cell proliferation by inducing apoptosis. This approach may offer a new therapeutic strategy for MTC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor.
  • Protein kinase C (PKC) signaling pathways are implicated in cancer cell proliferation and survival.
  • Targeting specific molecular pathways offers potential therapeutic strategies for MTC.

Purpose of the Study:

  • To investigate the role of PKC in human MTC cell proliferation using the PKC inhibitor Enzastaurin.
  • To elucidate the downstream effects of PKC inhibition on apoptosis and signaling pathways in MTC cells.
  • To evaluate the potential of targeting PKC as a therapeutic approach for MTC.

Main Methods:

  • Utilized human MTC primary cultures and the TT cell line.
  • Administered Enzastaurin, a PKC inhibitor.
  • Assessed cell proliferation, apoptosis (caspase-mediated), and protein phosphorylation (PKCβII, Akt, GSK).
  • Investigated PKCβII and PKCδ isoform expression and localization.

Main Results:

  • PKC inhibition by Enzastaurin significantly reduced MTC cell proliferation.
  • Enzastaurin induced caspase-mediated apoptosis in MTC cells.
  • PKC inhibition blocked IGF-I-stimulated calcitonin secretion.
  • Enzastaurin reduced phosphorylation of PKCβII (Thr500), Akt (Ser 473), and GSK (Ser9).
  • PKCβII inhibition and translocation to different subcellular compartments were observed.

Conclusions:

  • PKC plays a crucial role in controlling human MTC proliferation and survival in vitro.
  • PKC inhibition modulates apoptosis and affects key downstream signaling pathways.
  • Targeting PKC, particularly the PKCβII isoform, represents a promising therapeutic strategy for MTC management.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...